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Abstract
Objective: Alzheimer's disease (AD) is a progressive neurodegenerative disease of the central
nervous system (CNS). Recently, an increased interest in the role diet plays in the pathology of AD
has resulted in a focus on the detrimental effects of diets high in cholesterol and fat and the
beneficial effects of caloric restriction. The current study examines how dietary composition
modulates cerebral amyloidosis and neuronal integrity in the TgCRND8 mouse model of AD.
Methods: From 4 wks until 18 wks of age, male and female TgCRND8 mice were maintained on
one of four diets: (1) reference (regular) commercial chow; (2) high fat/low carbohydrate custom
chow (60 kcal% fat/30 kcal% protein/10 kcal% carbohydrate); (3) high protein/low carbohydrate
custom chow (60 kcal% protein/30 kcal% fat/10 kcal% carbohydrate); or (4) high carbohydrate/low
fat custom chow (60 kcal% carbohydrate/30 kcal% protein/10 kcal% fat). At age 18 wks, mice were
sacrificed, and brains studied for (a) wet weight; (b) solubilizable Aβ content by ELISA; (c) amyloid
plaque burden; (d) stereologic analysis of selected hippocampal subregions.
Results: Animals receiving a high fat diet showed increased brain levels of solubilizable Aβ,
although we detected no effect on plaque burden. Unexpectedly, brains of mice fed a high protein/
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low carbohydrate diet were 5% lower in weight than brains from all other mice. In an effort to
identify regions that might link loss of brain mass to cognitive function, we studied neuronal density
and volume in hippocampal subregions. Neuronal density and volume in the hippocampal CA3
region of TgCRND8 mice tended to be lower in TgCRND8 mice receiving the high protein/low
carbohydrate diet than in those receiving the regular chow. Neuronal density and volume were
preserved in CA1 and in the dentate gyrus.
Interpretation: Dissociation of Aβ changes from brain mass changes raises the possibility that
diet plays a role not only in modulating amyloidosis but also in modulating neuronal vulnerability.
However, in the absence of a study of the effects of a high protein/low carbohydrate diet on
nontransgenic mice, one cannot be certain how much, if any, of the loss of brain mass exhibited by
high protein/low carbohydrate diet-fed TgCRND8 mice was due to an interaction between
cerebral amyloidosis and diet. Given the recent evidence that certain factors favor the maintenance
of cognitive function in the face of substantial structural neuropathology, we propose that there
might also exist factors that sensitize brain neurons to some forms of neurotoxicity, including,
perhaps, amyloid neurotoxicity. Identification of these factors could help reconcile the poor
clinicopathological correlation between cognitive status and structural neuropathology, including
amyloid pathology.

Introduction
Alzheimer's disease (AD) is a neurodegenerative disease
of the central nervous system characterized by an accumulation of extracellular and cerebrovascular amyloid and
intracellular aggregated tau protein [1]. Amyloid deposits
are composed of amyloid-β peptide (Aβ), a 4 kD fragment
generated by proteolytic processing of the transmembrane
amyloid precursor protein (APP) [2]. The "amyloid cascade hypothesis" is one popular model of AD pathogenesis, and amyloidogenic processing by γ-secretases is
enhanced by mutations in either APP, presenilin 1, or
presenilin 2. Among the two major species of Aβ, the Cterminally extended Aβ42 is more highly amyloidogenic
than is the shorter but more abundant Aβ40. The ratio of
Aβ42/Aβ40 determines the ratio of Aβ clearance vs accumulation, and Aβ aggregates or oligomers are believed to
lead eventually to neuronal and synaptic dysfunction and
neuronal death [2]. In addition to the deleterious amyloidogenic pathway, an additional non-amyloidogenic
pathway has also been described. In this pathway, APP is
first cleaved by one of several α-secretases (e.g., ADAM10,
ADAM17) between positions 16 and 17 of the potential
Aβ fragment, thereby precluding amyloidogenesis [2].
Extensive data support the notion that diets low in calories, cholesterol, and saturated fatty acids, but rich in vegetables, fruits, and fish, may delay the onset and/or slow
the progression of clinical AD. The regulation of various
secretases by dietary components is also well-documented
(e.g., cholesterol regulation of γ-secretase; [3]). However,
there have been no head-to-head studies employing diets
high with various specified sources of calories to determine whether dietary composition has importance
beyond the known effect of high caloric intake to exacer-

bate amyloid pathology [4]. Therefore, in the current
study we evaluated the effects of 4 different diets in a
murine model of AD (TgCRND8) that harbors 3 mutations in the APP gene (K670M/N671L and V717F)[5].
Using this mouse model of AD, we set out to determine
whether different dietary compositions could modulate
Aβ levels, brain mass, neuronal density, and/or tissue volume in 3 subregions of the hippocampus.

Methods
Mice and diets
TgCRND8 mice (n = 57) were kept in static cages under a
12 hour light/dark cycle. Cages were changed at least once
each week, and the health of the mice was monitored
daily. Mice were weaned at the age of 4 weeks and placed
on one of four different diets: (1) regular or reference
commercial chow, RC; (2) high fat/low carbohydrate custom chow (60 kcal% fat/30 kcal% protein/10 kcal% carbohydrate), HF/LC; (3) high protein/low carbohydrate
custom chow (60 kcal% protein/30 kcal% fat/10 kcal%
carbohydrate), HP/LC; or (4) high carbohydrate/low fat
custom chow (60 kcal% carbohydrate/30 kcal% protein/
10 kcal% fat), HC/LF (Table 1) until the age of 18 weeks.
These custom diets were formulated by Research Diets,
Inc. (New Brunswick, NJ, USA) in collaboration with
Christopher O'Brien, Product Manager, Research Diets,
Inc, so as to avoid diets associated with predictable organ
toxicity. Mice were supplied with food and water ad libitum and were weighed weekly. At the age of 18 weeks,
mice were sacrificed via isoflurane inhalation, and the
brains were removed and weighed. The two cerebral hemispheres were separated for further experiments. One
hemisphere was snap-frozen in isopentane while the
other was immersion-fixed in 4% paraformaldehyde.
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Table 1: Chow nutritional information and ingredients

High fat

High carbohydrate

High protein

g%

kcal %

g%

kcal %

g%

kcal %

kcal %

39
13
35

30
10
60
100

29
58
4

30
60
10
100

65
11
14

60
10
30
100

29
58
13
100

Protein
Carbohydrate
Fat
Total
Total kcal/g

5.2

Ingredients

g

kcal

g

kcal

g

m cal

300
4.5
0
80
12.25
50
25
245
10
13
5.5
16.5
10
2
0

1200
18
0
320
49
0
225
2205
0
0
0
0
40
0
0

300
4.5
264
35
299.
50
25
20
10
13
5.5
16.5
10
2
0.21

1200
18
1056
140
1198
0
225
180
0
0
0
0
40
0
0

600
9
0
80
11.5
50
25
110
10
13
5.5
16.5
10
2
0.068

2400
36
0
320
46
0
225
990
0
0
0
0
40
0
0

773.8

4057

1055

4057

942.62

4057

Casein, 80 mesh
L-Cystine
Corn starch
Maltodextrin 10
Sucrose
Cellulose BW200
Soybean Oil
Lard
Mineral
Dialcium
Calcium
Potassium
Vitamin
Choline
Cholesterol
Total

Mix

Mix

Regular Chow

3.8

4.3

For the Regular Chow (reference Rodent Chow 5010) the ingredients were: Protein 24.6%, Fat (ether extract) 4.8%, Fat (acid hydrolysis) 5.5%,
Fiber (crude) 4.1%, Nitrogen-Free extract (by difference) 76.6%, Gross Energy kcal/g 4.14, Minerals and vitamins.

Genotyping
Mice were subjected to a tail biopsy, and DNA was
extracted using a Sigma DNA extraction kit (Sigma, St.
Louis, MO) according to the manufacturer's instructions.
The DNA was then amplified using APP-Hu-Forward
primer 5'-CCG ATG ATG ACG AGG ACG AT-3' and APPHu-Reverse primer 5'-TGA ACA CGT GAC GAC GCC GA3' in order to identify the 525 bp amplicon in TgCRND8
mice.
A ELISA
One cerebral hemisphere was homogenized 10% weight/
volume (w/v) in tissue homogenization buffer (250 mM
sucrose, 20 nM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA
+ protease inhibitors), then a 200 μl aliquot of extract was
added to a 440 μl aliquot of formic acid (FA) (minimum
95%), sonicated in ice for 1 minute and spun at 100,000
g for 1 hr at 4°C. Subsequently, a 210 μl aliquot was neutralized in 4 ml of FA neutralization buffer (1 M Tris base,
0.5 M Na2HPO4, 0.05% NaN3), stored at -80°C, and used
for Aβ40 and Aβ42 evaluation by ELISA (The Genetics
Company, Schlieren, Switzerland) according to the manufacturer's instructions. All values were then standardized

to the protein concentration of the brain homogenate.
Samples were analyzed in triplicate.
Immunohistochemistry and plaque density quantification
The second, unfrozen hemisphere was fixed in 4% paraformaldehyde in PBS. Immunohistochemistry was performed on every 10th of a series of 40 μm-thick sagittal
sections and every 5th of a series of 50 μm-thick coronal
section. Sections were chosen from a random starting
point and immunostained using anti-human APP antibody 6E10 (1:1,000) followed by a biotinylated monoclonal anti-mouse secondary antibody (1:200) protocol.
For plaque density determination, each brain tissue section was traced at 2.5× using StereoInvestigator (MBF Bioscience, Williston, VT). Systematic-random samples from
each brain tissue section were taken at a 20× magnification. Images were then acquired and volume and plaque
density were measured using Image J v1.38e (http://
rsbweb.nih.gov/ij). The results were expressed as mean ±
standard error of the mean (SEM).
Stereological analysis
Sections adjacent to those used for immunohistochemistry were used for Nissl staining. For stereologic analyses
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using the Optical Fractionator method, each section was
viewed on an Olympus BX51 microscope at low magnification (4×/0.32 N.A. Plan-Apochromat) and the regions
were contoured onto a live computer image using StereoInvestigator software. Counting of individual neurons
was performed at a higher magnification (60×/1.4 N.A.
Plan-Apochromat), using disector frames that were placed
within each contour using a systematic-random design
established by the software. For each section, the disector
height was kept constant in the region of interest in each
case.
Reference volume estimation
The Cavalieri principle was utilized for regional volume
estimation using a small 75 × 75 μm grid to obtain an
unbiased stereologic estimate of the independent volumes of subregions of the hippocampus: CA1, CA3, and
DG. CA2 was included within the CA1 contour for all
analyses.
Coefficients of error (CE)
The mean CEs for animals on the RC diet were 0.10, 0.12,
and 0.10 for CA1, DG, and CA3, respectively. The mean
CEs for animals on HF/LC diet were 0.12, 0.13, and 0.10,
respectively. Mean CEs for animals on the HC/LF diet
were 0.14, 0.14, and 0.11, respectively. The mean CEs for
animals on HP/LC diet were 0.14, 0.15, and 0.14, respectively.
Statistical analysis
ELISA of solubilizable Aβ40 and Aβ42, plaque density,
weight, brain weight, and regional neuronal counts and
volumes were analyzed using two-way analysis of variance
(ANOVA) with diet and sex as the independent variables.
Dunnett's multiple comparison procedure for pairwise
comparison of three diets with RC was based on Dunnett's T3 procedure for unequal variances. For weight, a
similar repeated measures ANOVA was performed to
assess changes with age. Linear trends in weight were also
analyzed. The subregions of the hippocampus were not
included as independent variables due to the fact that the
regions already have an inherent difference in cell density
and volume, rendering any comparison between them
within a single subject uninformative. α level was set at
0.05 for all analyses in the study, including the Dunnett
multiple comparisons of RC with the other three diets.
Attrition
Interindividual variations on Aβ levels in TgCRND8 mice
of this age range can vary from 6- to 10-fold [5]. "Outlier"
mice (i.e., with solubilizable Aβ levels two S.D. outside
the mean of the other individuals of their respective
groups; n = 6) were excluded from the analyses of solubilizable Aβ levels. Among the 51 mice remaining in the
study, 9 were excluded from the brain/total weight analy-

http://www.molecularneurodegeneration.com/content/4/1/40

sis because a substitute operator's data were highly erratic
and deemed unreliable. Consistent with the Chishti et al.
data on premature death of TgCRND8 mice [5], 6-9 mice
(29-39%) in each group died during the 18 wk trial (6 of
19 died on RC; 8 of 21 died on HF/LC; 7 of 24 died on
HP/LC; 9 of 23 died on HC/LF).

Results
The goal of this study was to evaluate the effect on Alzheimer's type neuropathology associated with one of four
different diets: regular or reference commercial chow (58
kcal% carbohydrate/29 kcal% protein/13 kcal% fat), RC;
high carbohydrate custom chow (60 kcal% carbohydrate/
30 kcal% protein/10 kcal% fat), HC/LF; high fat custom
chow (60 kcal% fat/30 kcal% protein/10 kcal% carbohydrate), HF/LC; high protein custom chow (60 kcal% protein/30 kcal% fat/10 kcal% carbohydrate), HP/LC; on
solubilizable Aβ levels and neuronal loss in TgCRND8
plaque-forming mice. According to the two-way ANOVA,
diet (as a general variable) played a role in determining
both solubilizable Aβ40 levels (F(3,43) = 7.298, p < 0.0005)
and solubilizable Aβ42 levels (F(3,43) = 13.978, p <
0.0005). Sex also played a role in solubilizable Aβ40 and
Aβ42 levels with levels being higher in females than males
(Aβ40, F(1,43) = 7.685, p = 0.008; Aβ42, F(1,43) = 11.835, p
= 0.001). Interestingly, there was no interaction between
diet and sex for either solubilizable Aβ40 (F(3,43) = 0.770,
p = 0.517) or solubilizable Aβ42 (F(3,43) = 0.920, p =
0.439) demonstrating that the sex effect was similar
within each diet, and, correspondingly, that the diet effect
was similar within each sex.
Pairwise comparison of each diet to RC revealed that solubilizable Aβ42 levels were significantly increased in mice
fed with HF/LC diet (RC vs F-P 147.89 vs 227.03, p =
0.014), but no difference was found between solubilizable Aβ42 levels of mice fed with HP/LC or HC/LF diets as
compared to RC (HP/LC 130.89, p = 0.862; HC/LF
152.48, p = 1.000) (Figure 1). For solubilizable Aβ40,
results approached statistical significance for the HF/LC vs
RC comparison (RC vs HF/LC 26.77 vs 47.94, p = 0.064),
while neither HP/LC nor HC/LF diets affect solubilizable
Aβ40 levels as compared to RC (HP/LC 29.83, p = 0.966;
HC/LF 29.19, p = 0.971).
The observation that the commercial diet (58 kcal% carbohydrate/29 kcal% protein/13 kcal% fat) and the custom HC/LF diet (60 kcal% carbohydrate/30 kcal%
protein/10 kcal% fat) yielded identical results tends to
exclude the possibility that any variations were attributable to the custom formulation per se. The elevation in solubilizable Aβ levels in the brains of HF/LC diet-fed
TgCRND8 mice was in accordance with data obtained in
other laboratories that directly connected high fat/high
cholesterol diets with amyloidosis and conventional
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gests that the higher levels of solubilizable Aβ that we
observed in our HF/LC diet-fed mice might involve primarily non-plaque forms of Aβ (e.g., oligomeric Aβ).
We then evaluated the effect of diets on the weight of the
mice. At baseline, at the age of 4 weeks, there was no difference in body weight of the mice according to sex or diet
(Table 2; Figure 2). By week 6 (i.e., only two weeks into
the 4-diet protocol), we observed an effect of diet on body
weight (highest to lowest: HF/LC > HC/LF = RC > HP/LC)
and an effect of sex (higher weights of males than of
females), but no interaction between these two factors.
Pairwise comparison showed the HF/LC and HC/LF diets
were significantly different from RC, while HP/LC diet
was not.

neuropathology
High
solubilizable
Figure
fat/low
1 Aβ42
carbohydrate
levels in diet
a murine
is associated
model ofwith
aggressive
increased
AD
High fat/low carbohydrate diet is associated with
increased solubilizable A 42 levels in a murine model
of aggressive AD neuropathology. TgCRND8 mice (n =
51) were fed for 14 weeks with regular commercial chow
(RC), high fat custom chow (HF), high protein custom chow
(HP), or high carbohydrate custom chow (HC). [N.B., diet
groups are named by either major component only (HF, HP,
HC) or by an abbreviation indicating both major and minor
components (HF/LC, HP/LC, HC/LF); HF or HF/LC = high
fat/low carbohydrate custom chow (60 kcal% fat/30 kcal%
protein/10 kcal% carbohydrate); HP or HP/LC = high protein/low carbohydrate custom chow (60 kcal% protein/30
kcal% fat/10 kcal% carbohydrate); HC or HC/LF = high carbohydrate/low fat custom chow (60 kcal% carbohydrate/30
kcal% protein/10 kcal% fat)]. At the end of this period, brains
were harvested, and levels of Aβ42 were evaluated as
described in Methods. Statistical significance (p = 0.014) was
determined by pairwise comparison to RC. Data represent
means ± S.D.

measures of soluble and insoluble Aβ [6-8]. However, in
our experiment, cholesterol was added to the RC, HC/LF,
and HP/LC diets in order to bring those custom diets up
to an identical level of cholesterol content to that present
in the HF/LC diet. Therefore, elevations in solubilizable
Aβ levels in HF/LC diet-fed TgCRND8 mice were not
attributable cholesterol but to dietary fats other than cholesterol.
A two-way ANOVA for differences in plaque density
showed no statistically significant effect of diet (F(3, 23) =
1.039, p = 0.394), sex (F(1, 23) = 0.277, p = 0.603), or
diet*sex interaction (F(3,23) = 0.237, p = 0.870). This sug-

At week 17, body weights of the mice differed by diet, but
overall, there was no effect of sex (Table 2; Figure 2). A significant diet*sex interaction indicated that the weights of
the male mice were higher than those of females in the
RC, HP/LC, and HC/LF diets (M vs F, RC 24.7 g vs 20.8 g,
HP/LC 21.4 g vs 17.8 g, HC/LF 29.6 g vs 27.1 g), while
mice fed with HF/LC diet showed the opposite pattern
with females being heavier than males (M vs F, HF/LC
33.5 g vs 43.7 g).
We performed a two-way ANOVA by diet and sex for
repeated measures of body weight from week 6 through
week 17. As shown (Table 3; Figure 2), as expected, the
body weight of the mice was affected by age. There were
significant age*diet and age*diet*sex interactions, while
the age*sex interaction was only a trend that approached
significance. ANOVA of linear trends from the repeated
measures analysis showed comparable results, demonstrating that the age interactions primarily reflected linear
trends. The age*diet interaction showed a greater increase
in the HF/LC group than in the other groups. The
age*diet*sex interaction in the HF/LC diet group showed
a greater increase among females than males, while
increases for males were at least as large as for females in
the other diets.
We then evaluated the weights of the brains at time of
death and compared them by two-way ANOVA. While
diet affected the weight of the brain (F(3,34) = 5.413, p =
0.004), neither sex (F(1,34) = 0.0025, p = 0.972) nor
diet*sex interaction (F(3,34) = 0.381, p = 0.997) affected
the brain weight. A pairwise analysis showed that mice fed
with HF/LC and HC/LF diets had brain weights equal to
mice fed the RC diet (RC vs F-P 0.535 g vs 0.540 g, p =
0.972; vs C-P 0.538 g, p = 0.997), while mice fed the HP/
LC diet had a significantly lower brain weight compared
to RC (RC vs P-P 0.535 g vs 0.514 g, p = 0.032) (Figure 3).
The brain/total weight ratios (brain weight as % of total
weight) were [HC/LF] 1.929 ± 0.227 (SD) (n = 10); [HP/
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Figure
Body
weights
2
of mice on various diets
Body weights of mice on various diets. Body weights of TgCRND8 mice were measured weekly from week 4 until week
17 (n = 57). The figures represent the weight difference depending on different diets in the whole group (A) as well in each different diet (B). [N.B., diet groups are named by either major component only (HF, HP, HC) or by an abbreviation indicating
both major and minor components (HF/LC, HP/LC, HC/LF); HF or HF/LC = high fat/low carbohydrate custom chow (60 kcal%
fat/30 kcal% protein/10 kcal% carbohydrate); HP or HP/LC = high protein/low carbohydrate custom chow (60 kcal% protein/
30 kcal% fat/10 kcal% carbohydrate); HC or HC/LF = high carbohydrate/low fat custom chow (60 kcal% carbohydrate/30 kcal%
protein/10 kcal% fat)]. Data represent means ± S.D.

LC] 2.668 ± 0.397 (n = 13); [HF/LC] 1.413 ± 0.307 (n =
10); [RC] 2.418 ± 0.321 (n = 9). Therefore, the brain
weight as % of total weight tended to be highest in the
HP/LC group and lowest in the HF/LC group.
There was a significant Pearson correlation of neuronal
count and volume estimate (r = 0.420, p < 0.001) among
the subset of mice studied. There were no significant
effects of diet, sex, or diet*sex interaction for neuronal

count or volume in any of the three hippocampal subregions: dentate gyrus, CA1, and CA3. The mean ± standard
error of the mean (SEM) for each subregion is presented
in Figure 4. In CA3, for neuronal count, the HP/LC mean
was only 52% of the RC mean, and the HP/LC volume
was only 70% of the RC volume, but the comparisons
were not significant (p = 0.308 and p = 0.282, respectively). On the other hand, when HP/LC vs RC for the CA3
region were compared without adjustment for multiple
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Table 2: Two-way ANOVA of body weight by diet and gender, at weeks 4, 6, and 17, with Dunnett's pairwise comparison of RC to
other diets, using Dunnett's T3 procedure for unequal variances.

Two-Way ANOVA

Pairwise comparison

Week 4

F

df

p

p

diet

0.424

3, 49

0.736

RC vs HP

0.939

gender

1.644

1, 49

0.206

RC vs HF

0.975

diet * gender

1.008

3, 49

0.397

RC vs HC

0.700

Two-Way ANOVA

Pairwise comparison

Week 6

F

df

p

p

diet

31.614

3, 19

< 0.0005

RC vs HP

0.271

gender

10.211

1, 49

0.002

RC vs HF

< 0.0005

diet * gender

0.894

3, 49

0.451

RC vs HC

0.037

Two-Way ANOVA

Pairwise comparison

Week 17

F

df

p

diet

52.588

3, 19

< 0.0005

RC vs HP

0.085

gender

0.003

1, 49

0.954

RC vs HF

< 0.0005

diet * gender

8.236

3, 49

< 0.0005

RC vs HC

0.001

comparisons, the approximate t-tests assuming unequal
variances yielded p values that approached statistical significance (neuronal count: t = 2.092, df = 7.37, p = 0.073;
neuronal volume: t = 2.223, df = 5.84, p = 0.069). This
raises the possibility that hippocampal CA3 was involved
in the loss of brain mass reflected in the diminished brain
mass in HP/LC diet-fed TgCRND8 mice. However, in the
absence of a cohort of HP/LC diet-fed nontransgenic

p

mice, we cannot be certain what role, if any, was played by
diet alone vs the interaction of cerebral amyloid with diet.

Discussion and conclusion
Effects of various diets on clinical and experimental AD
pathology have been reported in the literature, including
(a) high carbohydrate diets, (b) restricted calorie diets, (c)
the ketogenic diet, and (d) diets high or low in cholesterol

Table 3: Repeated measures ANOVA of body weight with Huynh-Feldt correction of the degrees of freedom for violation of the
sphericity assumption, and ANOVA of linear trend from the repeated measures analysis.

Repeated measures analysis

Linear trend analysis

F

df

p

F

df

p

age

181.784

2.981, 146.086

< 0.0005

306.212

1, 49

< 0.0005

age * diet

14.587

8.944, 146.086

< 0.0005

23.942

3, 49

< 0.0005

age * gender

2.554

2.981, 146.086

0.058

3.495

1, 49

0.068

age * diet *gender

5.971

8.944, 146.086

< 0.0005

9.365

3, 49

< 0.0005
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Figure
Brain
weights
3
of mice on various diets
Brain weights of mice on various diets. Brain weights
from TgCRND8 mice (n = 42) maintained on diets with various sources of calories. Statistical significance (p = 0.032) was
determined by pairwise comparison to RC. [N.B., diet
groups are named by either major component only (HF, HP,
HC) or by an abbreviation indicating both major and minor
components (HF/LC, HP/LC, HC/LF); HF or HF/LC = high
fat/low carbohydrate custom chow (60 kcal% fat/30 kcal%
protein/10 kcal% carbohydrate); HP or HP/LC = high protein/low carbohydrate custom chow (60 kcal% protein/30
kcal% fat/10 kcal% carbohydrate); HC or HC/LF = high carbohydrate/low fat custom chow (60 kcal% carbohydrate/30
kcal% protein/10 kcal% fat)]. Data represent means ± S.D.

and other fats. Under certain circumstances, high carbohydrate diets have been reported to exacerbate the pathology of AD in experimental animals [9]. Mice given 10%
sucrose-sweetened water in order to induce glucose intolerance, hyperinsulinemia, and hypercholesterolemia,
showed a 2-3-fold increase in levels of insoluble Aβ in
their brains [9]. In the current study, we did not observe
any association of brain weight loss, Aβ levels, or hippocampal integrity with either of two diets (one commercial,
one custom) in which most calories were derived from
carbohydrates [9]. A growing body of work implicates
insulin resistance as a key feature of carbohydrate-related
disturbances in Aβ metabolism [10], possibly explaining
the apparent discrepancy between our study and that of
Cao et al. [9], since our mice were not diabetic. A caloric
restriction (CR) diet has been shown to attenuate amyloidosis in murine and monkey models [5,11].
A ketogenic diet (low in carbohydrates, high in fat) has
been reported to reduce brain Aβ levels in a mouse model
[12]. This is somewhat surprising since several studies in
the literature show a robust association of HF/LC diet with
increased solubilizable brain Aβ levels [6-8]. Here, we
confirmed the generally-held association of high fat diet
with increased Aβ accumulation, but, since all our diets
contained identical levels of cholesterol, the solubilizable
Aβ levels as measured in our HF/LC diet-fed mice must be
due to fats other than cholesterol.

Figure 4 mice
Stereologic
TgCRND8
estimates
raisedofon
hippocampal
various diets
subregions of
Stereologic estimates of hippocampal subregions of
TgCRND8 mice raised on various diets. HF, high fat
custom chow; HC, high carbohydrate custom chow; HP, high
protein custom chow; RC, regular commercial chow. Vertical bars are means ± SEMs. A) Neuronal counts (n = 20). B)
Volume estimation by Cavalieri principle (n = 22). [N.B., diet
groups are named by either major component only (HF, HP,
HC) or by an abbreviation indicating both major and minor
components (HF/LC, HP/LC, HC/LF); HF or HF/LC = high
fat/low carbohydrate custom chow (60 kcal% fat/30 kcal%
protein/10 kcal% carbohydrate); HP or HP/LC = high protein/low carbohydrate custom chow (60 kcal% protein/30
kcal% fat/10 kcal% carbohydrate); HC or HC/LF = high carbohydrate/low fat custom chow (60 kcal% carbohydrate/30
kcal% protein/10 kcal% fat)].

A typical "Western diet," containing 40% saturated fatty
acids and 1% cholesterol, was reported to be associated
with increased brain Aβ levels in a murine model of AD
when compared with a diet enriched in docosahexaenoic
acid (DHA) [13]. An omega-3 fatty acid-enriched diet was
reported to reduce the amyloid burden in an AD mouse
model [14]. In a clinical study of the possible associations
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between intake of specific types of fat and AD in a cohort
of 815 65-year-old patients, intake of saturated fat and
trans-unsaturated fat was correlated with an increased risk
for clinical AD, while high intake of unsaturated, unhydrogenated fats was correlated with decreased risk [15].
Therefore, it is possible that it is specifically the saturated
fat content of a diet--and not its cholesterol content -- that
modulates Aβ metabolism. Some fats (e.g., DHA) are
reported to be relatively protective, and it is worth noting
that mice fed HF/LC diets showed no loss of brain weight
or hippocampal integrity despite the higher levels of solubilizable Aβ. These data are consistent with observations
that clinical dementia in humans correlates best with atrophy and not with neuropathological burden [16-21].
The most unexpected result of our study was the loss of
overall brain mass associated with a HP/LC diet that,
notably, did not exacerbate solubilizable Aβ levels or
amyloid pathology. It is worth noting that a major confound in the field of Alzheimer's disease mouse modeling
has been the conspicuous absence of neuronal loss in
these transgenic mouse models. Indeed, this widely confirmed precedent led us not to include nontransgenic
mice in our studies of the effects of custom diets.
TgCRND8 mice, because of their aggressive amyloid
pathology, are relatively insensitive to modulators of amyloidosis, and this may explain the minimal effect that we
observed for dietary fat. However, the malignant amyloid
pathology may well increase the sensitivity for detecting
modulators of amyloid toxicity. This may explain why we
observed the loss of brain mass with the HP/LC diet, but
this conclusion cannot be drawn until we examine the
effect of this HP/LC diet on the brains of nontransgenic
mice.
The "encephalization quotient" (EQ; brain weight/body
weight) is modulated by both genetic and dietary factors
during brain development [22,23], but the effect of diet
on EI in adult animals is less well-studied. The EQ in our
study was highest among the HP/LC mice and lowest
among the HF/LC group. Typically, protein deprivation is
associated with low brain weight and low EQ [22]. Conversely, high fat diet is believed to have facilitated the evolution of higher EQ [23]. On the surface, then, our
observations run counter to other reported effects on EQ.
Interestingly, protein-carbohydrate ratio has been demonstrated to modulate brain excitotoxicity differentially as a
function of age. A high carbohydrate/low protein (HC/
LP) diet has been reported to increase excitotoxicity in the
hippocampus and hypothalamus of young rats, while,
conversely an HC/LP diet has been associated with
decreased excitotoxicity in the same brain regions in older
rats. However, potentially relevant to our result, a high
protein-low carbohydrate (HP/LC) diet has been reported

http://www.molecularneurodegeneration.com/content/4/1/40

to associate with enhanced excitotoxicity specifically in
the aged brain [24]. Since Aβ is known to lower the threshold for glutamatergic excitoxicity in cultured neurons
[25], it is conceivable that high protein diet could play a
role in Aβ- related neurodegeneration via aging-dependent sensitization to glutamatergic excitotoxicity. Further
experiments (including studies of nontransgenic mice)
will be required to determine whether the trend toward
lower neuronal counts and decreased volume in the hippocampal CA3 subregion might be related to Aβ toxicity
and might reach statistical significance using larger
cohorts. These data, if specifically associated with the presence of cerebral Aβ amyloid, suggest that a diet rich in protein might enhance neuronal vulnerability to
amyloidosis.
Of course, regardless of what happens in the mouse models, the more important question is whether these data
have implications for the human aging brain and/or the
human AD brain. Given the association of high protein
diet with aging-related neurotoxicity [24], one wonders
whether particular diets, if ingested at particular ages,
might increase susceptibility to incidence or progression
of AD. This can only be established by prospective randomized double blind clinical trials of various diets. This
would be a challenging undertaking but potentially
worthwhile if there is a serious possibility for modifying
the course of AD by via manipulating dietary composition.
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